Ericsson (Nasdaq: ERIC) has signed a five-year deal with TeliaSonera AB (Nasdaq: TLSN) covering managed services in Sweden and elsewhere in Scandinavia. The agreement is actually a renewal and extension of a contract that was first signed in 2010, and the vendor says the contract extension will expand its footprint into eight new regions. On Friday shares of Ericsson (NASDAQ:ERIC) closed at $12.32. Company’s sales growth for last 5 years was 1.70% and EPS growth for next 5 years is recorded as 8.25%.
Encana Corporation (NYSE:ECA) stated that it plans to maintain the strength of its balance sheet in 2015 and will not increase any debt. Moreover, the proceeds from this sale along with its previously announced midstream assets sale would be used to support the company in this weakened pricing market. Encana Corporation (NYSE:ECA) in last trading activity increased 0.60% to close at $13.38. Company weekly performance is 4.61% while its quarterly performance stands at -25.46%. Encana Corporation (NYSE:ECA) is -45.65% away from its 52 week high.
NPS Pharmaceuticals, Inc. (NASDAQ:NPSP), which is in the process of being acquired by Shire, has been boosted by the news that the US Food and Drug Administration has approved Natpara for hypoparathyroidism. Specifically, Natpara (recombinant human parathyroid hormone) has got the green light to control hypocalcemia (low blood calcium levels) in patients with hypoparathyroidism, a rare disease that affects 60,000 people in the USA. On last trading day NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) remains unchanged to close at $45.64. Its volatility for the week is 0.48% while volatility for the month is 3.34%. NPSP’s sales growth for past 5 years was 8.70% and its EPS growth for past 5 years was 26.90%. NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) monthly performance is 26.92%.
Shares of Amedisys (NASDAQ:AMED) have earned an average recommendation of “Hold” from the twelve analysts that are presently covering the company. Amedisys Inc. (NASDAQ:AMED) has 0.90% insider ownership while its institutional ownership stands at 99.00%. In last trading activity company’s stock closed at $28.68.
Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) on Jan. 22 announced the appointment of Thomas J. DesRosier, Esq. to the position of executive vice president, chief legal and administration officer, and secretary. Mr. DesRosier will be responsible for global legal operations, information technology and other administrative functions. He will report to ARIAD’s chairman and chief executive officer, Harvey J. Berger, M.D. On Friday shares of Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) closed at $6.10. Company’s sales growth for last 5 years was 45.10% and EPS growth for next 5 years is recorded as 41.40%.